- Home
- CCEL vs NRSN Comparison
CCEL vs NRSN Comparison
Compare CCEL & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- NRSN
- Stock Information
- Founded
- CCEL 1989
- NRSN 2017
- Country
- CCEL United States
- NRSN Israel
- Employees
- CCEL N/A
- NRSN N/A
- Industry
- CCEL Managed Health Care
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- NRSN Health Care
- Exchange
- CCEL Nasdaq
- NRSN Nasdaq
- Market Cap
- CCEL 35.8M
- NRSN 29.8M
- IPO Year
- CCEL 1997
- NRSN 2021
- Fundamental
- Price
- CCEL $4.30
- NRSN $1.20
- Analyst Decision
- CCEL Hold
- NRSN Buy
- Analyst Count
- CCEL 1
- NRSN 2
- Target Price
- CCEL N/A
- NRSN $14.00
- AVG Volume (30 Days)
- CCEL 4.3K
- NRSN 381.2K
- Earning Date
- CCEL 10-15-2025
- NRSN 12-17-2025
- Dividend Yield
- CCEL 9.30%
- NRSN N/A
- EPS Growth
- CCEL N/A
- NRSN N/A
- EPS
- CCEL N/A
- NRSN N/A
- Revenue
- CCEL $31,747,500.00
- NRSN N/A
- Revenue This Year
- CCEL $0.30
- NRSN N/A
- Revenue Next Year
- CCEL N/A
- NRSN N/A
- P/E Ratio
- CCEL N/A
- NRSN N/A
- Revenue Growth
- CCEL N/A
- NRSN N/A
- 52 Week Low
- CCEL $4.00
- NRSN $0.81
- 52 Week High
- CCEL $9.10
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- CCEL 51.29
- NRSN 57.01
- Support Level
- CCEL $4.04
- NRSN $0.98
- Resistance Level
- CCEL $4.45
- NRSN $1.24
- Average True Range (ATR)
- CCEL 0.13
- NRSN 0.13
- MACD
- CCEL 0.03
- NRSN 0.02
- Stochastic Oscillator
- CCEL 67.26
- NRSN 76.51
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.